This phase 2 randomized clinical trial evaluates the efficacy and safety of Sym004 (a mixture of futuximab and modotuximab) for the treatment of refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy.
http://ift.tt/2nLHspY
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου